I believe that patients and families of patients with prevalent heart disease must not be unfamiliar with the term right ventricular hypertrophy, then, what exactly is right ventricular hypertrophy a disease? This question must be many people are not very clear. Today I will introduce you to the right ventricular hypertrophy. Pulmonary arterial hypertension is caused by a variety of etiological causes of pulmonary vascular bed involvement and progressive increase in pulmonary circulatory resistance, ultimately leading to a class of pathophysiological syndromes of the right heart failure, pulmonary arterial hypertension women more than men, about the ratio of 3~4:1, but in children patients, the male and female ratio does not differ. Pulmonary hypertension can involve people of all ages, including the elderly and young children, but at the time of diagnosis the average age is 36 years, with a predominance of young patients. In patients/children with congenital heart disease, due to hemodynamic changes, pulmonary blood flow is significantly increased, exceeding the storage capacity of the pulmonary vascular beds, which, over time, causes an increase in pulmonary arterial pressure. It is important to note that there are many causes of pulmonary hypertension other than congenital heart disease. If no cause can be found, the cause may be primary pulmonary hypertension, which requires medication to lower pulmonary artery pressure. Patients with pulmonary hypertension usually have no obvious symptoms in the early stages, and the most common clinical manifestation is exertional dyspnea. In patients with pulmonary arterial hypertension, 60% of them have dyspnea as the main complaint, while 98% of them have shortness of breath after activity when examined. Therefore, the misdiagnosis rate is extremely high. Because pulmonary hypertension can be caused by a variety of diseases, so it is also important to pay attention to the symptoms of related diseases, in the process of disease progression patients may also gradually appear lower extremity swelling, ascites, loss of appetite, increased blood volume, fatigue aggravation. Congenital heart disease is a very important factor in secondary pulmonary hypertension, congenital heart disease is mainly left to right shunt disease, that is, the body circulation to the pulmonary circulation shunt disease, such as ventricular septal defect, atrial septal defect, arterial conduit failure and so on. There is also a secondary form of pulmonary hypertension, which is sloughed-off pulmonary hypertension. It is caused by mitral stenosis, mitral valve insufficiency, etc. Firstly, mitral stenosis or insufficiency will lead to the elevation of pulmonary venous pressure, and then through the reverse conduction of the pulmonary vascular bed, leading to a slow increase in pulmonary arterial pressure, and finally leading to persistent arterial hypertension. There is no specific cure for pulmonary hypertension. The goal of treatment is to improve the patient’s symptoms and quality of life and to stop the progression of the disease. Traditional therapeutic options include anticoagulation, oxygenation, cardiotonic, diuretic and calcium antagonist with limited efficacy. Endothelin receptor antagonists, prostacyclin and phosphodiesterase inhibitors have been widely used internationally to effectively treat this disease, but these drugs are expensive and it is difficult for Chinese patients to bear the cost on their own. Therefore, we call on the whole society to pay attention to this disease with an aggressive prognosis, and to screen, diagnose and treat the disease at an early stage in order to contain it.